NCT07034690

Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

A Prospective, Type I Hybrid Effectiveness-implementation, Open Label, Randomized Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in at- Risk Adult Patients From Abu Dhabi, United Arab Emirates (UAE) With Dyslipidemia

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 326 (estimated)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with dyslipidemia who are at high risk or very high risk of cardiovascular events.

Detailed description

The treatment of interest is a lipid optimization program in the form of a health education intervention delivered via clinic visits (every 4 months) and virtual sessions (between each clinic visit). No active drug treatment will be provided. The intervention in this study will involve the implementation of a lipid optimization, education program for patients at high risk and very high risk of cardiovascular events.

Conditions

• Atherosclerotic Cardiovascular Disease

Interventions

Type	Name	Description
OTHER	Educational Material	Health Education Intervention delivered via clinic visits (every 4 months) and virtual sessions (between each clinic visit)
OTHER	Standard of care	Standard of care

Timeline

• Start date: 2025-11-26
• Primary completion: 2026-06-23
• Completion: 2027-06-30
• First posted: 2025-06-24
• Last updated: 2026-01-30

Locations

1 site across 1 country: United Arab Emirates